Vertex Secures Alyftrek Coverage in England; Merck Starts Phase 3 Trials of HIV Drug

Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.

Merck sends new monthly oral PrEP to Phase 3 after earlier islatravir setback

KIGALI, RWANDA — Three years after a safety disappointment halted earlier plans for a once-monthly HIV PrEP candidate, Merck is back in the late stages of development with a next-generation effort. The New Jersey company said ...

FDA to review MSD’s doravirine/islatravir NDA for HIV-1 treatment

The FDA has accepted MSD’s doravirine/islatravir new drug application (NDA) for review to treat adults with virologically suppressed HIV-1.